Seminars in Oncology Nursing
Volume 24, Issue 1 , Pages 49-56 , February 2008

Advances in Chemotherapy for Non–Small Cell Lung Cancer

  • Elizabeth S. Waxman

      Affiliations

    • Corresponding Author InformationAddress correspondence to Elizabeth S. Waxman, RN, MSN, AOCN®, Department of Thoracic/Head & Neck Medical Oncology, M.D. Anderson Cancer Center, 1400 Holcombe Blvd, Unit 432, Houston, TX 77030

References 

  1. Ihde DC. Chemotherapy of lung cancer. N Engl J Med. 1992;327:1434–1441
  2. Bunn PA. The expanding role of cisplatin in the treatment of non-small cell lung cancer. Semin Oncol. 1989;16:10–21
  3. Bunn PA. Review of therapeutic trials of carboplatin in lung cancer. Semin Oncol. 1989;16:27–33
  4. Bunn PA, Kelly K. New Chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin Cancer Res. 1998;4:1087–1100
  5. Knight EW, Lagakos S, Stolbach L, et al. Adriamycin in the treatment of far advanced lung cancer. Eur J Cancer. 1976;60:939–941
  6. Loeher PJ, Birch R, Kramer BS, et al. Ifosfamide plus n-acetylcysteine in the treatment of small cell and non-small cell carcinoma of the lung: a Southeastern Cancer Study Group Trial. Cancer Treat Rep. 1986;70:919–920
  7. Soscinski MA, Morris DE, Masters GA, et al. Chemotherapeutic management of stage IV non-small cell lung cancer. Chest. 2003;123(suppl):226s–243s
  8. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ. 1995;311:899–909
  9. Spiro SG, Rudd RM, Souhami RL, et al. Chemotherapy versus supportive care in advanced non-small cell lung cancer: improved survival without detriment to quality of life. Thorax. 2004;59:828–836
  10. Cullen MH, Billingham LJ, Woodroffe CM, et al. Mitomycin, ifosfamide, and cisplatin in unresectable non-small cell lung cancer: effects on survival and quality of life. J Clin Oncol. 1999;17:3188–3194
  11. Johnson SW, O'Dwyer PJ. Pharmacology of cancer chemotherapy: cisplatin and its analogues. In:  DeVita VT,  Hellman S,  Rosenberg SA editor. Cancer: principles and practice of oncology. Ed 7. Philadelphia, PA: Lippincott Williams and Wilkins; 2005;p. 344–358
  12. Ardizzoni A, Boni L, Tiseo M, et al. Cisplatin-versus carboplatin-based chemotherapy in first line treatment of advanced non-small cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst. 2007;99:847–857
  13. Berghmans T, Paesmans M, Sculier JP. Cisplatin or carboplatin for the treatment of non-small cell lung cancer: do they have equivalent efficacy?. Lung Cancer. 2001;34:15–17
  14. Soria J-C, LeChevalier T. Is cisplatin still the best platinum compound in non-small cell lung cancer?. Ann Oncol. 2002;13:1515–1517
  15. Einhorn LH. Carboplatin versus cisplatin in lung cancer. Lung Cancer. 2005;49(suppl 3):s32–s35
  16. Hotta K, Matsuo K, Yeoka H, et al. Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small cell lung cancer. J Clin Oncol. 2004;22:3852–3859
  17. Zojwalla NJ, Raftopoulos H, Gralla RJ. Are cisplatin and carboplatin equivalent in the treatment of non-small cell lung cancer (NSCLC)? Results of a comprehensive review of randomized studies in over 2500 patients. Proc Am Soc Clin Oncol. 2004;23:14S;(abstr 7068)
  18. Chan AM, Mao AJ, Wu T, et al. Meta-analysis comparing carboplatin and cisplatin-based chemotherapy in advanced non-small cell lung cancer. Proc Am Soc Clin Oncol. 2005;24:16S;(abstr 7128)
  19. Govindan R. Chemotherapy for metastatic NSCLC: current status and future directions. Nat Clin Pract Oncol. 2005;2:238–239
  20. Rudd RM, Gower NH, Spiro SG, et al. Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small cell lung cancer: a phase III randomized study of the London Lung Cancer Group. 2005;23:142–153.
  21. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med. 2002;346:92–98
  22. National Comprehensive Cancer Network. Non-Small Cell Lung Cancer Practice Guidelines in Oncology. v.1.2007. Available at: http://www.nccn.org (accessed Feb 19, 2007).
  23. Fossella FV. Second-line chemotherapy for non-small cell lung cancer. Curr Oncol Rep. 2000;2:96–101
  24. Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol. 2000;18:2354–2362
  25. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 2000;18:2095–2103
  26. Smit EF, Mattson K, von Pawel J, et al. Alimta (pemetrexed disodium) as second-line treatment of non-small cell lung cancer: a phase II study. Lung cancer previously treated with chemotherapy. Ann Oncol. 2003;14:455–460
  27. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004;22:1589–1597
  28. Viele CS. Keys to unlock cancer: targeted therapy. Oncol Nurs Forum. 2005;32:935–940
  29. Hicklin DJ, Ellis LM. Role of vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005;23:1011–1027
  30. Shepherd FA, Pereira JR, Ciuleanu T, et al. Erlotinib in previously treated non-small cell lung cancer. N Engl J Med. 2005;353:123–132
  31. Hoff PM. Future directions in the use of antiangiogenic agents in patients with colorectal cancer. Semin Oncol. 2004;31(suppl 17):17–21
  32. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small cell lung cancer. N Engl J Med. 2006;355:2542–2550
  33. National Cancer Institute Fact Sheet - Bevacizumab (Avastin) for the treatment of solid tumors: questions and answers. Available at: http://www.cancer.gov/cancertopics/factsheet/AvastinFactSheet (accessed Sept 21, 2007).
  34. Kozloff M, Cohn A, Christiansen N, et al. Safety of bevacizumab among patients receiving first line chemotherapy for metastatic colorectal cancer: preliminary results from a larger registry in the U.S. J Clin Oncol. 2005;23(suppl):16s;(abstr)
  35. Betticher D, Schmitz SF, Totsch M, et al. Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic lung of survival in patients with stage IIIa pn2 non-small cell lung cancer: a multicenter phase II trial. J Clin Oncol. 2003;21:1752–1759
  36. Burdett S, Stewart LA, Rydzewska LA. A systematic review and meta-analysis of the literature: chemotherapy and surgery versus surgery alone in non-small cell lung cancer. J Thorac Oncol. 2006;1:611–621
  37. Pisters KMW, Ginsberg RJ, Giroux DJ, et al. Induction chemotherapy before surgery for early-stage lung cancer: a novel approach. J Thorac Cardiovasc Surg. 2000;119:429–439
  38. Bunn PA, Mault J, Kelly K. Adjuvant and neoadjuvant chemotherapy for non-small cell lung cancer: a time for reassessment?. Chest. 2000;117:119–122
  39. Aerts JGJV, Surmont V, van Klaveren RJ, et al. A phase II study of induction therapy with carboplatin and gemcitabine among patients with locally advanced non-small cell lung cancer. J Thorac Oncol. 2006;1:532–536
  40. Abratt RP, Lee JS, Han JY, et al. Phase II trial of gemcitabine-carboplatin-paclitaxel as neoadjuvant chemotherapy for operable non-small cell lung cancer. J Thorac Oncol. 2006;1:135–140
  41. Carbone DP, Minna JD. Chemotherapy for non-small cell lung cancer. BMJ. 1995;311:889–890
  42. Arriagada R, Bergman B, LeChevalier T. et al, on behalf of The International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small cell lung cancer. N Engl J Med. 2004;350:351–360
  43. Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs observation in resected non-small cell lung cancer. N Engl J Med. 2005;352:2589–2597
  44. Douillard JY, Rosell R, Delena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomized controlled trial. Lancet Oncol. 2006;7:719–727
  45. Pignon JP, Tribodet H, Scagliotti GV. et al, on behalf of The LACE Collaborative Group. Lung Adjuvant Cisplatin Evaluation (LACE): a pooled analysis of five randomized clinical trials including 4,584 patients. Proc Am Soc Clin Oncol. 2006;24:18S;(abstr 7008)
  46. Gridelli C, Perrone F, Monfardini S. Lung cancer in the elderly. Eur J Cancer. 1997;33:2313–2314
  47. Gridelli C. The ELVIS trial: a phase III study of single agent vinorelbine as first line treatment in elderly patients with advanced non-small cell lung cancer. The Oncologist. 2001;6(suppl 1):4–7
  48. Langer CJ, Manola J, Bernardo P, et al. Cisplatin-based therapy for elderly patients with advanced non-small cell lung cancer: implications of Eastern Cooperative Oncology Group 5592: a randomized trial. J Natl Cancer Inst. 2002;94:172–181
  49. Chen YM, Perng RP, Tsai CM, et al. A phase II randomized study of paclitaxel plus carboplatin or cisplatin against chemo-naïve inoperable non-small cell lung cancer in the elderly. J Thorac Oncol. 2006;1:141–145

PII: S0749-2081(07)00141-6

doi: 10.1016/j.soncn.2007.11.012

Seminars in Oncology Nursing
Volume 24, Issue 1 , Pages 49-56 , February 2008

Article Tools